61 results about "Medication intervention" patented technology

The invention discloses a wearable / handheld personal communication device with hardware and software sensor modules that sense and analyze all caregiver prescribed / monitored user-lifestyle activities, and deploys such analysis in improving user's overall health in terms of reduced risks for all-cause morbidities / mortalities and eventually a life without drugs. Termed Rx Zero, such method may be prescribed not just for maintaining a healthy lifestyle, but for treatment of chronic diseases with intent to wean the patients to minimal or zero pharmacological intervention, or in combination with medications to improve prognosis of the disease under treatment.The benefits of the Rx Zero method of the present invention extend not only to the individual and the community through high quality healthcare at lower cost, but payers by reducing the loss ratio on account of reduced cost of medical claims, and to the caregivers in terms of an effective tool that disseminates, implements and redefines “Primary Health Care” and “Prevention” at levels beyond the terms' currently understood scope that has transformed healthcare to sickcare.

The present invention provides a means for performing scalable, computationally efficient and rapid simulations of complex or complex adaptive systems realized through the dynamic interaction of multiple modeling components to generate outputs suited to decision support, analysis and planning. In the context of disease modeling, these outputs can be used for analyzing the impact of disease and the potential value of the use of pharmaceutical and non-pharmaceutical interventions.

The invention is applicable to the technical field of medicines, and provides a medication information management system, method and terminal equipment. The medication information management system comprises: a medication knowledge base module which includes basic information of medicines, contents of medicine components, medicine compatibility and other information, a prescription / advices of doctors audit module which is used for auditing outpatient and emergency prescriptions and advices of doctors for hospitalization according to the medication knowledge base module and the basic information, diagnosis information, allergic history information and other information of a patient, and sending the audit result to a drug dispensing system and a liquid mixing system of a pharmacy, and a medication integration module which is used for performing extraction and collection on the past medication information, medication in hospitals, medication for outpatient and discharge medication of thepatient, sorting the extracted and collected information according to the drugs, the usage and dosage and the medication course of treatment, performing medication intervention or medication guidanceon the medication situation of the patient according to the sorting result, and generating a medication instructor. Therefore, the medication information management system, method and terminal equipment can solve the problems of acquisition, utilization, processing and integration of medication information, and can realize effective beforehand intervention for medication.

The invention relates to a medicinal composition for treating an ischemia reperfusion injury, particularly a hepatic ischemia reperfusion injury, and a preparation method and application thereof. The composition comprises an M-cholinergic receptor blocker and a cholinesterase inhibitor, has a simple and convenient preparation process, is safe to use, has an obvious curative effect, can be used for obviously improving the cell apoptosis caused by the ischemia reperfusion injury and overcomes the side effects caused by existing common medicaments. The invention expands novel medical application of an existing muscarinic receptor blocker and also provides a novel medicine intervention means for preventing and treating the ischemia reperfusion injury. The medicinal composition is suitable for large-scale production and commercial application in the industries of medicine, reagents and the like, has excellent application prospect and has obvious social benefits and economic benefits.

The invention discloses a prediction method for a small-spatial-scale infectious disease space-time propagation mode. The method comprises the steps: fusing a constructed SEIR model with an estimated resident trip OD matrix, forming a small-spatial-scale infectious disease epidemic situation propagation SEIR model which is based on population flow and is fused with non-drug intervention measures, and employing different intervention measures to deal with an infectious disease epidemic situation scene; multi-source data such as mobile phone communication signaling are collected and arranged, a space-time transmission mode of infectious diseases is iteratively simulated, intervention prevention and control measures are refined into indexes and parameters to be brought into an SEIR model, and the development trend of epidemic situations and the accumulated number of cases under different scenes are simulated; therefore, the small-space-scale diffusion path, epidemic curve and space-time propagation network of the infectious diseases in the city can be explored; meanwhile, multi-source driving factors and public health intervention measures are considered, and the prediction result is more reliable; more accurate study and judgment are provided for the development situation of early epidemic situations, and the practicability is higher.

The invention provides a drug network pharmacology intelligent and quantitative analysis method and system based on a network target original theory, wherein the method and system are used for measuring the overall effect of intervening a disease biological network by drugs (including various drug types such as Chinese and western drugs). The method can integrate qualitative and / or quantitative biological information related to diseases and drugs, takes the disease biological network as a target and realizes effect measurement of drug intervention on the disease biological network from the system and overall perspective, and reveals the overall action mechanism of the drugs. The method provides a qualitative and quantitative selectable measurement mode, measures the drug intervention network effect by adopting biological function multi-scale qualitative analysis and / or time-space multi-dimensional quantitative analysis, and provides a new key technique for breaking through the limitation of a traditional experience-based or single-target-based drug research mode, understanding a drug network regulation mechanism, and quickly and intelligently discovering pharmacodynamic substances, action mechanisms, curative effect objective indexes and clinical indications and the like.

The invention relates to the technical field of healthy foods, and specifically discloses a non-drug intervention dietary food for promoting disease rehabilitation. The dietary food comprises one or more selected from the group consisting of substitutional tea, composite vegetable and fruit powder, solid beverage, cereals and medicinal and edible products, wherein a composition is prepared by mixing the vegetable and fruit powder, solid beverage powder, the cereals and the medicinal and edible products; and the ratio of the components of the composition is (20%-50%): (25%-40%): (20%-30%). According to the invention, on the basis of the principle of homology of medicine and food, through scientific proportioning in combination with an ultramicro powder preparation technology, a compositionof one or more selected from the group consisting of the vegetable and fruit powder, the solid beverage, the cereals and the medicinal and edible products is formed; through addition of the substitutional tea, a reasonable dietary supplement is provided for eaters, so cell nutrition and functional states of the eaters are fully supplemented and improved; cell functions and vitality are improved; sub-health is rapidly improved; and recovery of chronic diseases is promoted.

The invention discloses a modeling method of an uyghur medicine abnormal balgam syndrome and disease animal model, the model, and a disproof and comprehensive evaluation method, and belongs to the field of uyghur medicine andrology. The modeling method of the abnormal balgam syndrome and animal model is characterized in that after the model is formed, regrouping, disproof and comprehensive evaluation are performed. The method comprises the following steps: dividing experimental animals into a control group and a modeling group; breeding the control group with conventional diet in a conventional environment; placing the modeling group into an artificial climate box (temperature is set to 6 DEG C and humidity is set to 85%-95%), and breeding the modeling group with wet and cold feed, while both the control group and the modeling groups drink water randomly; and dynamically observing biological representation, penis erection function and sexology change of each group in the whole course. The modeling method of the uyghur medicine animal model, the model, and the disproof and comprehensive evaluation method provided by the invention has reliability, feasibility and favorable repetitiveness and scientificity, and can be used for biological fundamental research and pharmaceutical intervention research of uyghur medicine abnormal balgam syndrome and abnormal balgam impotence disease.

The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament.The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.

Contemplated methods and devices for coagulation control allow to establish a more constant dosage of required medication and to quantify / take into account patient-specific sensitivity to warfarin and Vitamin K by using logit (1 / INR) as the dependent variable to so stabilize the variance across all values of INR. Moreover, it should be noted that such use simplifies the relation between INR and dose of coumarins or Vitamin K and reduces the number of parameters to be estimated for each patient.

The invention relates to a prediction method and system for the survival rate of an acute myocardial infarction patient within 5 years. The method comprises the steps: acquiring clinical data of the acute myocardial infarction patient during hospital admission; establishing a prediction model according to the clinical data, establishing a column diagram of the survival rate within 5 years, calculating a total risk score, and then calculating a prediction value of the survival rate of the patient within 5 years; and outputting a predicted value of the survival outcome occurrence probability ofthe patient within 5 years. External verification proves that the method is suitable for Chinese people, statistical analysis is carried out by combining various potential risk factors influencing poor prognosis such as hospitalization baseline vital signs of acute myocardial infarction patients, operations and drug intervention, laboratory examination and imaging examination, factors related to the survival rate within 5 years are screened out, a prediction system for the survival rate of the acute myocardial infarction patient within 5 years is established, and a risk quantitative value is provided for clinicians to predict the survival rate of the acute myocardial infarction patient within 5 years more comprehensively and accurately.

The invention discloses a construction method of a drug evaluation model for dermal pathology of a tuberculosis rabbit. The method comprises: selecting a rabbit, injecting an immune drug into rabbit, conducting BCG (Bacillus Calmette Guerin) vaccine immune injection on the 15th to 20th day of drug intervention, and carrying out bacterial and pathological examination so as to construct a pathological model. The method of the invention establishes a pathological model of drug intervention on drug cutaneous tuberculosis with obvious symptoms so as to conduct visual research on tuberculosis pathology and bacterial pathogenicity, thus providing a visual animal model for vaccines and screening of drugs treating a tuberculosis necrotic liquefied cavity. And the model is stable and repeatable. The invention establishes a drug intervention procedure and observation indexes for research of drug intervention on a tuberculosis granuloma liquefaction process, and also provides a research basis for probing an immune mechanism about the formation of a tuberculosis liquefied cavity.

The invention discloses a drug intervention target spot for treating keloid skin tissue fibrosis. The target spot is a TWIST1 gene and an encoding protein thereof. The gene provided by the invention is highly expressed in keloid-derived fibroblasts. TWIST1 is subjected to small-molecule inhibitor drug harmine treatment, fibrosis of the keloid-derived fibroblasts and TGF-[beta] signal channel related gene expression can be remarkably reduced, and then, pathological fibrosis of keloid skin tissues is relieved. On the basis, drugs which include a small-molecule inhibitor and are designed by aiming at the target spot can be used for treating and relieving the keloid. The invention provides a new drug target spot for treatment of the keloid.

A pharmaceutical formulation capable of supplying replacement blood volume and tissue oxygenation as well as other functions, such as procoagulation and pharmacological interventions, in order to enhance survivability in patients with severe blood loss. The invention also discloses a formulation and method of using the formulation in bridging severe blood loss using a multifunctional blood substitute in a prehospital setting.

The invention relates to a method for treating coagulation disorders by adopting a vitamin K1 fat milk injection. Particularly, an emulsion composition is prepared from vitamin K1, soybean oil, phospholipid, glycerinum and water. The emulsion composition is prepared through technologies of preparing a water phase, preparing an oil phase, preparing crude milk, performing high pressure emulsifying,performing hot-pressing sterilizing and the like. The method further comprises the step of detecting related substances, in particular to an impurity B on the emulsion composition obtained after hot-pressing sterilizing. The invention further relates to pharmaceutical application of the emulsion composition for treating coagulation disorders caused by dyssynthesis of coagulation factors II, VII, IX and X caused by medicine intervention of vitamin K deficiency or vitamin K activity interference. The invention further relates to a method for determining related substances, particularly the impurity B in the vitamin K1 composition through an HPLC method. The emulsion composition has one or more technical effects shown in the specification.

The invention relates to a composition for protecting the liver, detoxifying, preventing and treating liver and related metabolic diseases. The main ingredients are 200-250 parts of kudzu root, 200-220 parts of poria cocos, 50-60 parts of dandelion, and licorice 40-50 parts, 160-180 parts of chicory, 5-6 parts of soybean oligosaccharides, 10-15 parts of soybean peptide powder, 5-8 parts of glycine, 2-3 parts of lycopene; the auxiliary material is 5-6 parts of edible corn starch 6 parts, 4‑6 parts of sodium carboxymethylcellulose. The invention also provides a preparation method of the composition. The prescription of the present invention adopts natural traditional Chinese medicine materials of the same origin as food and medicine, supplemented with nutrients, scientific compatibility, promotes drug excretion, protects the liver, improves liver cell function, and performs non-drug intervention on fatty liver and related metabolic system problems , the same source of food and medicine avoids secondary damage to the liver caused by drug treatment, and achieves the effect of "clearing the liver and protecting the liver without hurting the liver".

The present invention provides a compound of Formula (I) being capable of modulating the activity of histone lysine demethylase (KDM), pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The compound of Formula (I) acts as KDM inhibitor with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to KDM dysregulation.

The invention discloses application of a microbial marker in cerebral infarction diagnosis and treatment effect evaluation. Specifically, the microbial marker is Vampirovibrio. According to the application of the microbial marker in cerebral infarction diagnosis and treatment effect evaluation, the drug intervention effect of a subject can be judged by detecting the abundance of the Vampirovibrioin a sample of the subject. Meanwhile, the invention also provides the application of the microbial marker in treatment of cerebral infarction.

The invention discloses application of vinpocetine in preparation of a medicament for preventing and / or treating acute mountain sickness caused by rush entry into plateaus, and further discloses application of vinpocetine in preparation of a medicament for preventing and / or treating myocardial tissue edema and / or brain tissue edema, myocardial tissue inflammatory reaction and / or brain tissue inflammatory reaction caused by low-pressure and low-oxygen environments at the rush entry into plateaus. The invention explores a prevention and treatment effect of vinpocetine on the brain tissue and myocardial tissue edema caused by low pressure and low oxygen at the rush entry into plateaus, and the results show that vinpocetine can down-regulate the expression level of aquaporin genes AQP1 in myocardial tissues and brain tissues under low-pressure and low-oxygen conditions of the plateaus to reduce brain edema and myocardial edema caused by low pressure and low oxygen of the plateaus. The invention simulates the plateau environment at the altitude of 7000m and observes the protective effect of vinpocetine on the myocardial edema and brain edema of rats induced by the low pressure and low oxygen of the plateaus, thereby providing new application and new targets for drug intervention for clinical application of vinpocetine.

The invention relates to a pharmaceutical composition for treating and repairing spinal cord injury and application of the pharmaceutical composition. According to the invention, research finds that Rab3A plays a key role in SCI and interacts with Spastatin to regulate and control outward growth of neurite. The identification of differentially expressed proteins in SCI proves that the expression level of Rab3A is down-regulated in the SCI process. In addition, the invention also finds that Rab3A can generate physical interaction with the Spastatin, and the degradation of the Spastatin is regulated and controlled through a lysosome way, so that the function of the Spastatin is influenced. These findings collectively emphasize the signal transduction pathway, where Rab3A mediates spastin degradation to modulate the formation and growth of neurite branches. As SCI is a major cause of disability, repair of spinal cord structure defects caused by injury or degeneration is crucial in the field of modern regenerative medicine. Various drug intervention measures can be designed to treat SCI and assist in related tissue repair, and other cell intervention measures can be combined.

The invention relates to an infectious disease transmission simulation method and system, a terminal and a storage medium. Comprising the following steps: constructing an individual movement model according to multi-source data in a prevention and control area; constructing an individual-based space-time dynamic contact network based on the individual movement model; modeling is carried out according to non-drug intervention measures implemented in the prevention and control area; and building an individual-based infectious disease transmission model based on the dynamic contact network and the intervention measure modeling, and simulating the infectious disease transmission intensity in the prevention and control area through the infectious disease transmission model. The infectious disease transmission intensity of the prevention and control area is simulated through the infectious disease transmission model, fusion modeling of various non-drug intervention measures can be supported, the adherence degree of an individual to various intervention measures can be evaluated, the effectiveness of various non-drug intervention measures for inhibiting infectious disease transmission can be accurately evaluated, and the method is suitable for popularization and application. Therefore, future epidemic prevention and control can be systematically and scientifically assisted.

An apparatus, system, and method for the measurement, aggregation and analysis of data collected using non-contact or minimally-contacting sensors provides quality of life parameters for individual subjects, particularly in the context of a controlled trial of interventions on human subjects (e.g., a clinical trial of a drug, or an evaluation of a consumer item such as a fragrance). In particular, non-contact or minimal-contact measurement of quality-of-life parameters such as sleep, stress, relaxation, drowsiness, temperature and emotional state of humans may be evaluated, together with automated sampling, storage, and transmission to a remote data analysis center. One component of the system is that the objective data is measured with as little disruption as possible to the normal behavior of the subject. The system can also support behavioral and pharmaceutical interventions aimed at improving quality of life.

A risk-adjusted assessment of a target facility's quality measures (e.g. mortality rate, length of stay, readmission rate, complications rate, etc.) is determined with respect to the quality measures of a broader population base. Patient cohorts are identified corresponding to particular ailments or treatments, and the target facility's risk-adjusted quality measures are determined for each cohort. When a particular quality measure for a target cohort indicates poor performance, factors that are determined to be relevant to the patients' outcomes are identified and used to create a control group of patients in the broader population who exhibit similar factors but had better outcomes than the patients of the target cohort. The care process (treatments, medications, interventions, etc.) that each of the target patients received is compared to the care process that each of the control patients received, to identify potential root-causes of the poorer performance.

The invention discloses a circular non-coding RNA circSTK39 and an application of the circular non-coding RNA circSTK39 in prevention and treatment of atherosclerosis. According to the present invention, complete transcriptome high-throughput sequencing is performed on the artery tissue in a mouse AS model, and the circular non-coding RNA-circSTK39 with characteristics of expression in the advanced AS group and high conservative property is screened, wherein the circSTK39 in human is obtained after a DNA (deoxyribonucleic acid) sequence as shown in SEQ ID NO. 1 is transcribed. The invention finds that circSTK39 plays an important role in the whole occurrence and development process of atherosclerosis by exploring the regulation and control function of circSTK39 on proliferation and migration of vascular smooth muscle cells. According to the present invention, a target spot can be screened clinically, such that the early atherosclerosis can be subjected to drug intervention in time so as to delay or even reverse the disease. In the screening of the advanced atherosclerosis, the lesion development condition of a patient can be known, and clinical events can be timely intervened and avoided. Therefore, the invention provides a novel molecular marker and an intervention target for preventing and treating atherosclerosis.

The present invention provides a compound of Formula (I) being capable of modulating the activity of histone lysine demethylase (KDM), pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The compound of Formula (I) acts as KDM inhibitor with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to KDM dysregulation.

The present invention provides compositions and methods for treating hyperglycemia, insulin resistance, and associated organ damage, including in some embodiments diabetes mellitus (type 1 or 2), metabolic syndrome, obesity, fatty liver diseases, or kidney disease. In various embodiments, the invention involves administering a regimen of larazotide (or a derivative of larazotide) to a subject. In various embodiments, the regimen reduces dysfunction of the gastrointestinal epithelial barrier, thereby improving glycemic control. In various embodiments, the regimen of larazotide improves the effectiveness of conventional pharmaceutical interventions for hyperglycemia or diabetes mellitus.

The invention provides a neurotrophic keratitis (NK) mouse model, namely an AQP5-KO model mouse. The mouse model is constructed by reducing the expression quantity of a gene AQP5 or knocking out the gene AQP5. The AQP5-KO model mouse disclosed by the invention is high in repeatability and stable in model, is beneficial to research and drug intervention of a dry eye pathomechanism, and can avoid the influence of other influence factors on an experimental result. After the AQP5-KO model mouse is born, the characteristic change of corneal subepithelial nerve reduction occurs; and after birth, thecorneal sensitivity is obviously reduced, and the corneal sensitivity is not obviously changed along with increase of age.

The invention discloses a heart failure early detection method, and aims to introduce big data and an artificial intelligence technology into the field of medical health, discover various diseases andsyndromes, mine valuable information and provide a systematic decision for heart failure diagnosis and treatment. The method is characterized in that daily physiological data of a patient is collected through a cloud platform, and electrocardio data association relation analysis which describes massive medical data characteristics in a unified mode and meets complex semantics and a physiologicalindex similarity evaluation strategy based on a time sequence are provided, so that early detection and early warning of heart failure are carried out. According to the method, physiological data of electrocardio monitoring such as blood pressure, respiratory rate, heart rate and weight collected from 132 patients (47 decompensated events and 85 normal events) are used to verify that the proposedscheme is particularly suitable for detecting early heart failure decompensation, so that efficient, intelligent and personalized services are provided for users. The method is suitable for early detection of heart failure, so that the development of heart failure can be effectively delayed by changing the life style, conducting drug intervention and the like.

The invention discloses a drug intervention target for tumor-related secondary lymphedema. The target is a CLEC3B gene and an encoding protein thereof. The expression of the gene provided by the invention in adipose-derived stem cells derived from tumor-related secondary lymphedema patients is significantly up-regulated. The siRNA-mediated CLEC3B gene knock-down can significantly down-regulate fibrosis and TGF-beta signal pathway related gene expression, so that lymphedema adipose tissue fibrosis can be effectively relieved. On this basis, drugs including siRNA designed for the target can be used for treating and relieving lymphedema. The invention provides the new drug target for the treatment of lymphedema.